CompletedNCT01093937
Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolarity
Medication studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
Study information
Study start dateNovember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01093937
- Official title
Show the full official title
A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including varenicline.
Who was this study for?
Listed age limits: 18 years to 65 years.
